860 related articles for article (PubMed ID: 35339673)
1. Post-COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients.
Peghin M; De Martino M; Palese A; Gerussi V; Bontempo G; Graziano E; Visintini E; D'Elia D; Dellai F; Marrella F; Fabris M; Curcio F; Sartor A; Isola M; Tascini C
Clin Microbiol Infect; 2022 Aug; 28(8):1140-1148. PubMed ID: 35339673
[TBL] [Abstract][Full Text] [Related]
2. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients.
Peghin M; Palese A; Venturini M; De Martino M; Gerussi V; Graziano E; Bontempo G; Marrella F; Tommasini A; Fabris M; Curcio F; Isola M; Tascini C
Clin Microbiol Infect; 2021 Oct; 27(10):1507-1513. PubMed ID: 34111579
[TBL] [Abstract][Full Text] [Related]
3. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
4. Antibody response and risk of reinfection over 2 years among the patients with first wave of COVID-19.
Peghin M; De Martino M; Palese A; Chiappinotto S; Fonda F; Gerussi V; Sartor A; Curcio F; Grossi PA; Isola M; Tascini C
Clin Microbiol Infect; 2024 Apr; 30(4):522-530. PubMed ID: 38141821
[TBL] [Abstract][Full Text] [Related]
5. Long-term evolution of humoral immune response after SARS-CoV-2 infection.
Teyssou E; Zafilaza K; Sayon S; Marot S; Dropy M; Soulie C; Abdi B; Tubach F; Hausfater P; Marcelin AG; Boutolleau D;
Clin Microbiol Infect; 2022 Jul; 28(7):1027.e1-1027.e4. PubMed ID: 35307573
[TBL] [Abstract][Full Text] [Related]
6. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
[TBL] [Abstract][Full Text] [Related]
7. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
8. Evaluating immunity to SARS-CoV-2 in nursing home residents using saliva IgG.
Katz MJ; Heaney CD; Pisanic N; Smith L; Bigelow BF; Sheikh F; Boudreau A; Kruczynski K; Hsu YJ; Salinas AB; Cosgrove SE; Rock C
J Am Geriatr Soc; 2022 Mar; 70(3):659-668. PubMed ID: 35038344
[TBL] [Abstract][Full Text] [Related]
9. Post-COVID-19 Syndrome 2 Years After the First Wave: The Role of Humoral Response, Vaccination and Reinfection.
Peghin M; De Martino M; Palese A; Chiappinotto S; Fonda F; Gerussi V; Sartor A; Curcio F; Grossi PA; Isola M; Tascini C
Open Forum Infect Dis; 2023 Jul; 10(7):ofad364. PubMed ID: 37520419
[TBL] [Abstract][Full Text] [Related]
10. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
[TBL] [Abstract][Full Text] [Related]
11. Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study.
Li J; Ge M; Dai S; Song Q; Liu W; Wang Y; Xu W; Ma L
Front Immunol; 2022; 13():1030238. PubMed ID: 36420275
[TBL] [Abstract][Full Text] [Related]
12. Humoral SARS-CoV-2 Immune Response in COVID-19 Recovered Vaccinated and Unvaccinated Individuals Related to Post-COVID-Syndrome.
Gerhards C; Kittel M; Ast V; Bugert P; Froelich MF; Hetjens M; Haselmann V; Neumaier M; Thiaucourt M
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851668
[TBL] [Abstract][Full Text] [Related]
13. Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations.
Titova E; Kan VW; Lozy T; Ip A; Shier K; Prakash VP; Starolis M; Ansari S; Goldgirsh K; Kim S; Pelliccia MC; Mccutchen A; Megalla M; Gunning TS; Kaufman HW; Meyer WA; Perlin DS
Microbiol Spectr; 2024 Mar; 12(3):e0205023. PubMed ID: 38353557
[TBL] [Abstract][Full Text] [Related]
14. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
16. 15-month post-COVID syndrome in outpatients: Attributes, risk factors, outcomes, and vaccination status - longitudinal, observational, case-control study.
Augustin M; Stecher M; Wüstenberg H; Di Cristanziano V; Sandaradura de Silva U; Picard LK; Pracht E; Rauschning D; Gruell H; Klein F; Wenisch C; Hallek M; Schommers P; Lehmann C
Front Immunol; 2023; 14():1226622. PubMed ID: 37781408
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
19. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Serial Humoral Immune Response according to the Immunosuppressive Treatment after SARS-CoV-2 mRNA Vaccination.
Menjo H; Hasegawa M; Fujigaki H; Ishihara T; Minatoguchi S; Koide S; Hayashi H; Saito M; Takahashi K; Ito H; Yuzawa Y; Saito K; Tsuboi N
Intern Med; 2023 Dec; 62(23):3445-3454. PubMed ID: 37779074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
